David Scadden T.'s most recent trade in Agios Pharmaceuticals Inc was a trade of 1,400 Common stock done at an average price of $18.1 . Disclosure was reported to the exchange on July 10, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 10 Jul 2025 | 1,400 | 19,003 (0%) | 0% | 18.1 | 25,326 | Common stock |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 10 Jul 2025 | 1,400 | 17,603 (0%) | 0% | 40 | 56,000 | Common stock |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Jul 2025 | 1,400 | 27,707 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 15,768 | 15,768 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2025 | 2,816 | 2,816 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 17,603 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2025 | 2,120 | 0 | - | - | Restricted stock units | |
| Editas Medicine Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 37,500 | 37,500 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | David Scadden T. | Director | Sale of securities on an exchange or to another person at price $ 46.28 per share. | 11 Dec 2024 | 200 | 15,483 (0%) | 0% | 46.3 | 9,256 | Common stock |
| Agios Pharmaceuticals Inc | Scadden David T. | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2024 | 200 | 29,107 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | T. David Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.09 per share. | 11 Dec 2024 | 200 | 15,683 (0%) | 0% | 18.1 | 3,618 | Common stock |
| Carisma Therapeutics Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2024 | 38,700 | 38,700 | - | - | Stock Option (Right to Buy) | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 11,774 | 11,774 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2024 | 2,120 | 2,120 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jun 2024 | 3,388 | 15,483 (0%) | 0% | 0 | Common stock | |
| Editas Medicine Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 4,975 | 0 | - | - | Restricted stock unit | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jun 2023 | 4,975 | 12,095 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 18,958 | 18,958 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 3,388 | 3,388 | - | - | Restricted stock units | |
| Editas Medicine Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 29,307 | 29,307 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 4,975 | 4,975 | - | - | Restricted stock unit | |
| Editas Medicine Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 0 | - | - | Restricted stock unit | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2022 | 1,585 | 7,120 (0%) | 0% | 0 | Common stock | |
| Editas Medicine Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2021 | 11,538 | 11,538 | - | - | Stock Option (right to buy) | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,686 | 0 | - | - | Restricted stock units | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2021 | 1,686 | 5,535 (0%) | 0% | 0 | Common stock | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 8,888 | 8,888 | - | - | Stock options (right to buy) | |
| Agios Pharmaceuticals Inc | David T. Scadden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 May 2021 | 1,585 | 1,585 | - | - | Restricted stock unit |